Literature DB >> 9753400

Prognosis of ependymoma.

D Schiffer1, M T Giordana.   

Abstract

Ependymoma is a rare tumor entity. It affects children and adults and has four preferential locations: supra- and infra-tentorial, spinal, and conus-cauda-filum. For statistical reasons, therefore, it is difficult to identify prognostic factors in series from single institutions because of the limited number of cases. The problem is complicated by the existence of some variants and by the difficulty in recognizing the anaplastic variant, because the common criteria used for recognizing malignancy in gliomas are not completely reliable in ependymomas. Apart from age and location, many parameters have been considered for prognostic purposes, including extension of surgical removal and radiotherapy. Among histological factors, the number of mitoses, labelling indices of proliferation markers, and cell density turned out to be good parameters for prognostic purposes. An overview is given of the contributions in the literature, including our own, on this problem.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9753400     DOI: 10.1007/s003810050244

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  13 in total

1.  The role of resection alone in select children with intracranial ependymoma: the Canadian Pediatric Brain Tumour Consortium experience.

Authors:  Tamir Ailon; Christopher Dunham; Anne-Sophie Carret; Uri Tabori; P Daniel Mcneely; Shayna Zelcer; Beverley Wilson; Lucie Lafay-Cousin; Donna Johnston; David D Eisenstat; Marianna Silva; Nada Jabado; Karen Jane Goddard; Chris Fryer; Glenda Hendson; Cynthia Hawkins; Sandra Dunn; Stephen Yip; Ashutosh Singhal; Juliette Hukin
Journal:  Childs Nerv Syst       Date:  2014-11-13       Impact factor: 1.475

Review 2.  Pediatric surgical neuro-oncology: current best care practices and strategies.

Authors:  James T Rutka; John S Kuo
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

3.  Subtle clinical signs of a spinal cord ependymoma at the cervicothoracic level in an adult: a case report.

Authors:  Julie O'Shaughnessy; André Bussières
Journal:  J Can Chiropr Assoc       Date:  2006-12

Review 4.  [Infratentorial tumors].

Authors:  I Q Grunwald; C Veith; M Backens; C Roth; P Papanagiotou; W Reith
Journal:  Radiologe       Date:  2007-06       Impact factor: 0.635

5.  Establishment and characterization of clinically relevant models of ependymoma: a true challenge for targeted therapy.

Authors:  Su Guan; Ruijun Shen; Tiffany Lafortune; Ningyi Tiao; Peter Houghton; W K Alfred Yung; Dimpy Koul
Journal:  Neuro Oncol       Date:  2011-06-08       Impact factor: 12.300

Review 6.  Neurofibromatosis-2 and spinal cord ependymomas: Report of two cases and review of the literature.

Authors:  Dolly G Aguilera; Claire Mazewski; Matthew J Schniederjan; Traci Leong; William Boydston; Tobey J Macdonald
Journal:  Childs Nerv Syst       Date:  2010-12-04       Impact factor: 1.475

7.  The use of neoadjuvant chemotherapy to achieve complete surgical resection in recurring supratentorial anaplastic ependymoma.

Authors:  Elvis Terci Valera; Helio Rubens Machado; Antonio Carlos Santos; Ricardo Santos de Oliveira; David Araújo; Luciano Neder; Luiz Gonzaga Tone
Journal:  Childs Nerv Syst       Date:  2004-08-27       Impact factor: 1.475

Review 8.  Survival following treatment for intracranial ependymoma: a review.

Authors:  G Tamburrini; M D'Ercole; B L Pettorini; M Caldarelli; L Massimi; C Di Rocco
Journal:  Childs Nerv Syst       Date:  2009-04-22       Impact factor: 1.475

Review 9.  Ependymoma.

Authors:  Charles Teo; Peter Nakaji; Patricia Symons; Vivienne Tobias; Richard Cohn; Robert Smee
Journal:  Childs Nerv Syst       Date:  2003-05-22       Impact factor: 1.475

10.  Immunohistochemical markers for prognosis of ependymal neoplasms.

Authors:  Andrey Korshunov; Andrey Golanov; Valery Timirgaz
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.